Skip to main content


  • Research article
  • Open Access

Elevated levels of dehydroepiandrosterone as a potential mechanism of dendritic cell impairment during pregnancy

  • 1,
  • 1Email author,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 2
BMC Immunology201516:2

  • Received: 4 September 2014
  • Accepted: 11 December 2014
  • Published:



This study aimed to test the hypothesis that immune dysfunction and the increased risk of spontaneous abortion in pregnant women with hyperandrogenia (HA) are caused by the reduced tolerogenic potential of dendritic cells (DCs) that results from elevated levels of dehydroepiandrosterone sulfate (DHEAS).


The phenotypic and functional properties of monocyte-derived DCs generated from blood monocytes from non-pregnant women, women with a normal pregnancy, or pregnant women with HA, as well as the in vitro effects of DHEAS on DCs in healthy pregnant women were investigated.


In a normal pregnancy, DCs were shown to be immature and are characterized by a reduced number of CD83+ and CD25+ DCs, the ability to stimulate type 2 T cell responses and to induce T cell apoptosis. By contrast, DCs from pregnant women with HA had a mature phenotype, were able to stimulate both type 1 (IFN-γ) and type 2 (IL-4) T cell responses, and were characterized by lower B7-H1 expression and cytotoxic activity against CD8+ T cells. The addition of DHEAS to cultures of DCs from healthy pregnant women induced the maturation of DCs and increased their ability to activate type 1 T cell responses.


Our data demonstrated the reduction in the tolerogenic potential of DCs from pregnant women with HA, and revealed new mechanisms involved in the hormonal regulation of DCs mediated by DHEAS.


  • Dendritic cells
  • Dehydroepiandrosterone sulfate (DHEAS)
  • Pregnancy
  • Tolerogenic activity


The hypothesis that tolerance plays a major role in pregnancy was first proposed by P. B. Medawar more than 50 years ago [1]. Subsequent studies not only confirmed the assumptions of Medawar, but also resulted in significant progress towards understanding the phenomenon of immunological tolerance. It has become evident that despite the anatomical separation of the mother and fetus, the induction of tolerance requires the recognition of fetal antigens by maternal immune cells [2]. Tolerance induction involves several mechanisms, including immunological ignorance [3], T cell apoptosis and anergy [4,5], and immunosuppression mediated by both regulatory cells [6,7] and cytokines [8,9]. Furthermore, a key role for dendritic cells (DCs) in immune tolerance that occurs during pregnancy has been proposed.

DCs are best known as cells that can induce an adaptive immune response [10,11], although DCs were also recently shown to be capable of suppressing immune responses [12]. Initially, this tolerogenic activity was thought to be associated with an immature state of DCs or with the plasmacytoid DC subset [12,13]. However, subsequent studies showed that intermediate and mature DCs can also exhibit tolerogenic properties [14,15], and DC phenotypes can be influenced by various anti-inflammatory and immunosuppressive mediators [16-18]. DCs can acquire tolerogenic features upon exposure to prostaglandin E2, vitamin D3, HLA-G molecules, IL-21, IL-16, IL-4, thrombopoietin, M-CSF, G-CSF, HGF, VIP (vasoactive intestinal peptide), or TSLP (thymic stromal lymphopoietin), which are present in large amounts in the decidua [3,12,19,20]. Additionally, many apoptotic trophoblast cells enter the circulation during pregnancy, and their engulfment might also induce tolerogenic activity in DCs [21].

The functional activity of DCs has been shown to be controlled by hormones, including glucocorticoids and sex hormones, such as chorionic gonadotropin, estrogens, and progesterone, which can increase the tolerogenic potential of DCs [22-27]. Therefore, it was suggested that hormones can modulate DCs and that the microenvironment represents a key factor that can trigger and regulate immunological tolerance [28]. Accordingly, dysfunction in hormone secretion pathways can significantly affect the tolerogenic potential of DCs.

Previously, we showed that pregnant women with elevated levels of DHEAS, which results from minor forms of adrenal hyperandrogenia (HA), exhibit immune abnormalities. In particular, they show a reduced number of CD4+CD25+ regulatory T cells and an increased number of activated NK cells compared to women with a normal pregnancy [29]. Because similar immune abnormalities have been described in women with recurrent miscarriages [30,31], we suggested that immune dysfunction might be the cause of the increased abortion rate in pregnant women with elevated levels of DHEAS [32,33]. The stimulatory effect of DHEAS on the immune system that results in the activation of natural killer cells (NK cells) and Th1 cells is well-known [34]. We have also shown that DHEAS can induce the in vitro maturation and Th1-stimulating activity of DCs [35]. Therefore, we suggest that immune dysfunctions in pregnant women with increased levels of DHEAS could result from impaired immunological tolerance, and the reduction in the tolerogenic potential of DCs might be caused by elevated concentrations of DHEAS.

To test this hypothesis, we studied the phenotypic and functional properties of monocyte-derived DCs in non-pregnant women, women with a normal pregnancy, and pregnant women with elevated levels of DHEAS. We also assessed in vitro the effect of DHEAS on DCs in healthy pregnant women.



This study included three groups of women (Table 1). The control group included 42 fertile non-pregnant women (who had at least one successful pregnancy and no previous abortions) whose menstrual cycles were regular (mean age 30.2 ± 0.2 years). All women in the control group had normal serum levels of DHEAS. Study group I included 66 healthy pregnant women who did not have any infectious or endocrine diseases, or clinical signs of hyperandrogenism, and who exhibited normal serum levels of DHEAS (<1.8 mg/ml). Study group II included 44 pregnant women with elevated levels of DHEAS (>1.8 mg/ml) that could be attributed to minor forms of adrenal hyperandrogenia and were not associated with polycystic ovaries. All pregnant women were under 22 weeks of gestation. The groups of pregnant women were comparable in age (26.1 ± 0.1 and 26.9 ± 0.1 years, respectively) and gestation period (14.2 ± 0.2 and 15.1 ± 0.1 weeks, respectively). All patients participating in this study had no acute exacerbations of chronic diseases, acute infections, or other endocrine disorders. All individuals provided written informed consent to participate in this study that was approved by the local ethical committee of the Institute of Fundamental and Clinical Immunology.
Table 1

Characteristics of groups of patients



Non-pregnant women (n = 42)

Pregnant women with normal levels of DHEAS < 1.8 (n = 66)

Pregnant women with elevated levels of DHEAS >1.8 (n = 44)


27.2 ± 0.2

26.1 ± 0.1

26.9 ± 0.1

Age at menarche

13.2 ± 0.1

13.1 ± 0.1

14.3 ± 0.1

Spontaneous abortion




Gestation period


14.2 ± 0.2

15.1 ± 0.1

DHEAS (μg/ml)

0.58 ± 0.03

0.61 ± 0.04

4.3 ± 0.23





Testosterone (nmol/l)




Clinical signs of


- hyperandrogenism




- menstrual irregularities




- hair growth in androgen-


Dependent areas




- acne




- oily seborrhea




Generation of DCs

Peripheral blood mononuclear cells (MNCs) were obtained by density gradient centrifugation (Ficoll-Paque, Sigma–Aldrich) of heparinized whole blood samples. DCs were generated by culturing the plastic-adherent MNC fraction in 6-well plates (Nunclon, Denmark) in RPMI-1640 medium (Sigma–Aldrich) supplemented with 0.3 mg/ml L-glutamine, 5 mM HEPES buffer, 100 μg/ml gentamicin, and 5% fetal calf serum (FCS, Sigma–Aldrich) in the presence of recombinant human GM-CSF (40 ng/ml, Sigma–Aldrich) and rIFN-α (Roferon-A, 1000 U/ml, Roche, Switzerland) for 4 days at 37°С in a 5% СО2 atmosphere (IFNα-DCs). The resulting DCs were then stimulated with 10 μg/ml lipopolysaccharide (LPS E. coli 0114: B4, Sigma–Aldrich) as a maturation stimulus for an additional 24 h. In some experiments, DHEAS (Sigma–Aldrich, 10−6 М) was added to the DC culture along with LPS. The viability of IFN-DCs, as determined by Trypan blue exclusion, was at least 93–95% in all cases.

Flow cytometric analysis

Flow cytometry was performed using FACS Calibur and CellQuest software (BD Becton Dickinson). DC phenotypes were determined following direct single- or two-color staining with FITC-, PE- or PerCP-conjugated mAb specific for CD83, CD25, HLA-DR, CD14, or B7-H1 (BD PharMingen). In each experiment, isotype-matched control mAbs were included to measure non-specific background staining.

Analysis of intracellular expression and production of cytokines

The capacity of DCs to activate T cell cytokine production was tested in allogeneic mixed lymphocyte cultures (MLCs). Freshly isolated monocyte-depleted allogeneic MNCs (1 × 105 per well) were cultured in complete culture medium supplemented with 10% FCS with or without DCs (1 × 104 per well) in 96-well plates for 72 h. For the last 18 h of culture, 10 μg/ml Brefeldin A (Sigma–Aldrich) was added. Cells were harvested, washed, and incubated with APC-conjugated anti-CD3 mAb (BD Pharmingen) at room temperature for 15 min. Cells were then permeabilized with 0.2% Tween-20 (Sigma–Aldrich), stained with FITC-labeled anti-IFN-γ or PE-labeled anti-IL-4 mAb (BD Pharmingen), and analyzed by flow cytometry.

To measure IFN-γ and IL-4 secretion by T cells, after 5 days supernatants of co-cultured MNCs and allogenic IFN-DCs (at a MNC-to-DC ratio of 10:1) were collected and assayed using IFN-γ and IL-4 ELISA kits according to the manufacturer’s instructions (Vector-Best, Russia).

Analysis of apoptosis

To analyze the apoptosis of CD3+CD4+ and CD3+CD8+ Т cells, IFN-DCs were co-cultured with 1 × 105 allogenic MNCs from healthy donors in 96-well round-bottom plates at a DC-to-MNC ratio of 1:10. After 3 days of incubation, cells were harvested, washed, and incubated with APC-conjugated anti-CD3 and PerCP-conjugated anti-CD4 Abs (BD Pharmingen) at room temperature for 15 min. The percentage of apoptotic cells was determined using a FITC-conjugated Annexin V Apoptosis Detection Kit I according to the manufacturer’s recommendations (BD Pharmingen). Apoptotic cells were identified by the binding of FITC-conjugated Annexin V and PI within the CD3+CD4+ or CD3+CD8+ (CD4) gates. Data were expressed as the percentage of positive cells among total CD3+CD4+ and CD3+CD8+ Т cells. At least 10,000 events were gathered from each sample.

Statistical analysis

Statistical analysis was performed using Statistica 6.0 software for Windows (StatSoft Inc.). Data were expressed as means ± SE. The nonparametric Mann–Whitney U test was used to determine statistically significant differences. A threshold for significance of p < 0.05 was used.


Because the functional activity of DCs largely depends on their maturity, we compared surface marker expression of DCs generated in normal pregnant women (NP-DCs) and pregnant women with hyperandrogenia (HA-DCs). DCs of non-pregnant fertile women were used as a control (control DCs). As shown in Figure 1, a two-fold lower percentage of CD83+ cells (a marker of mature monocyte-derived DCs) and CD25+ cells (a marker of activated mature DCs) were generated from normal pregnant women than from non-pregnant controls (рU < 0.01). Meanwhile, HA-DCs were not found to have a reduced percentage of CD83+ and CD25+ cells as compared to control DCs. Accordingly, the rate of CD83+ and CD25+ cells in the HA-DC population was two-fold higher than in NP-DCs. The percentage of CD14+ cells (a monocyte/macrophage marker) in HA-DC cultures was also significantly higher than in NP-DCs. To explain the cause of the simultaneous increase in CD83+ and CD14+ cells, we characterized the co-expression of these molecules by DCs. In cultures of NP-DCs, about half of CD83+ cells co-expressed CD14 (4.3% ± 0.9%) on their surface. The proportion of CD14+CD83+ cells in HA-DCs was three times higher than that of women with a normal pregnancy (up to 14.0% ± 2.5%, pU < 0.01), and this explained the observed simultaneous increase in both CD14+ and CD83+ cells in the HA-DC populations.
Figure 1
Figure 1

Phenotypic characteristics of IFN-α-DCs in normal pregnant women and pregnant women with hyperandrogenia. IFN-α-DCs were analyzed by flow cytometry for the expression of DC-related surface antigens in non-pregnant reproductive aged women (control group), normal pregnant women (NP-women), and pregnant women with hyperandrogenia (HA-women). (A) Histograms represent the expression of the indicated molecules (bold-line histograms) and the corresponding isotype controls (grey-filled histograms) in individual experiments. The relative percentage of positive cells (%) among the DCs are presented as means (± SE). (B) Gated HLA-DR+ IFN-α-DCs were analyzed for CD14 and CD83 staining. Representative stainings of IFN-α-DCs from NP-women (left, dot plots) and HA-women (right, dot plots) are shown.

To assess whether the impaired maturation/activation state of DCs could affect their functional activity, we further investigated the ability of DCs to stimulate T cell production of IFN-γ and IL-4 in a MLC. DCs from non-pregnant controls (Table 2) stimulated a five-fold increase in the number of CD3+IFN-γ+ T cells, but negligibly influenced the number of CD3+IL-4+ T cells. Similar data were also obtained from an analysis of IFN-γ and IL-4 secretion. The concentration of IFN-γ in the supernatant of MLC, stimulated by DCs from non-pregnant women, was significantly higher than that in cultures without DCs. However, DCs did not significantly stimulate IL-4 secretion.
Table 2

T1/T2-stimulatory activity of IFN-α-DCs


Culture conditions

Intracellular expression and production of the cytokines IFN-γ and IL-4


Control group (n = 10)

NP women (n = 8)

HA women (n = 8)








CD3+ IFN-γ+ (%)


1.5 ± 0.2


1.8 ± 0.5


1.8 ± 0.5


+ DCs

5.9 ± 0.6

5.2 ± 0.9

1.5 ± 0.27**

1.1 ± 0.2**

2.5 ± 0.3**#

2.0 ± 0.4**#

CD3+ IL-4+ (%)


1.7 ± 0.1


2.6 ± 0.4


3.3 ± 0.5


+ DCs

2.1 ± 0.4

1.3 ± 0.2

8.6 ± 1.0**

3.5 ± 0.4**

7.4 ± 1.0**

2.4 ± 0.5*

IFN-γ (pg/ml)


18.2 ± 5.7


16.5 ± 2.8


16 ± 3.0


+ DCs

353 ± 41

22.2 ± 3.1

63.4 ± 27.8**

3.4 ± 0.9**

218 ± 69* #

13.5 ± 3.1*#

IL-4 (pg/ml)


1.0 ± 0.08


1.0 ± 0.09


1.0 ± 0.12


+ DCs

2.0 ± 1.0

2.0 ± 1.0

4.6 ± 2.2

4.6 ± 2.2

5.4 ± 2.0*

5.4 ± 2.0*

Donor MNCs were co-cultured with allogenic IFN-α-DCs from non-pregnant women (control), normal pregnant women (NP), or hyperandrogenia pregnant women (HA) for 72 h at an MNC-to-DC ratio of 10:1. For the final 18 h of culture, 10 μg/ml Brefeldin A was added. Intracellular expression of IFN-γ and IL-4 was detected within the CD3+ gate by flow cytometry. To determine the levels of cytokine production by MNCs, cell-free supernatants were collected after 5 days of co-culturing donor MNCs and allogenic IFN-α-DCs from the control group, NP-women, or HA-women (at a MNC-to-DC ratio of 10:1) and were assessed for production of IL-4 and IFN-γ using specific ELISA kits. Data are presented as mean (± SE) cytokine concentrations (pg/ml) or the percentage of CD3+ cells from the indicated number of independent experiments. SI indicates the stimulation index, which was calculated as the ratio of cytokine concentrations (pg/ml) or intracellular cytokine expression (%) by MNCs in the presence or absence of DCs. *, pU < 0.05, **, pU < 0.01, compared to the control women group; #, pU < 0.05, compared to the NP-women group. Significant differences were detected using the Mann–Whitney U test.

Compared to control DCs, NP-DCs did not induce an increased number of CD3+IFN-γ+ T cells and stimulated less secretion of IFN-γ, but did induce almost a three-fold increase in CD3+IL-4+ T cells and moderately enhanced IL-4 production. HA-DCs also stimulated the increase in CD3+IFN-γ+ T cells and secretion of IFN-γ, although their stimulatory effect was significantly lower than that of control DCs. Additionally, HA-DCs retained the ability to stimulate T2-responses, in particular to induce CD3+IL-4+ T cells and increase IL-4 secretion.

To clarify whether the enhanced capacity of HA-DCs to stimulate IFN-γ production by T cells could be attributed to increased level of DHEAS, we studied the direct effects of the hormone on the T1-stimulated activity of NP-DCs. Treatment of NP-DCs with DHEAS induced pronounced Th1-stimulatory activity. Levels of IFN-γ in MLCs induced by DHEAS-modified NP-DCs were more than two-fold higher than that in the MLC, which were induced by intact NP-DCs (344 ± 160 vs. 144 ± 90 pg/ml; PU < 0.05). Therefore, our findings suggest that DHEAS in vitro has a pronounced up-regulating effect on Th1-stimulating capacity of NP-DCs.

Notably, DC tolerogenic activity might be associated with both the induction of Th2-responses and the ability of T cells to promote the apoptosis/anergy of cytotoxic T cells. Indeed, we recently found that donor IFN-α-DCs can induce T cell apoptosis via the PD-1/PD-L1 pathway, and enhanced expression of PD-L1 (B7-H1) on DCs could significantly increase their pro-apoptogenic activity in immunopathology [36,37]. Therefore, we compared the expression of B7-H1 and assessed DC cytotoxic activity in normal pregnant women and pregnant women with HA.

The percentage of B7-H1+ cells in the HLA-DR+ subset of control DCs (Figure 2) varied from 20% to 54%, and the average was 37.3% ± 3.4%. In normal pregnancy, the number of B7-H1+ DCs was significantly higher and reached an average of 85% ± 2.6%. The number of B7-H1+ cells in HA-DC cultures was significantly lower than in NP-DC cultures (73.7% ± 2.7% vs. 85% ± 2.6%, рU = 0.027). Representative histograms of DC expression of HLA-DR and B7-H1 in women with a normal pregnancy or a pregnancy with HA are shown in Figure 3.
Figure 2
Figure 2

Expression of B7-H1 molecules by IFN-α-DCs from healthy donors (HD), normal pregnant (NP) women, and pregnant women with hyperandrogenia (HA). Data are presented as means (± SE) percentage of cells positive for B7-H1 staining among all IFN-α-DCs expressing HLA-DR. *, pU < 0.05 indicates a significant difference compared to healthy donors (n = 12); #, pU < 0.05 indicates a significant difference between groups of NP-women (n = 6) and HA-women (n = 8); comparisons were made using the Mann–Whitney U test.

Figure 3
Figure 3

Expression of B7-H1 by IFN-α-DCs from healthy donors or pregnant women. Representative data from experiments performed with IFN-α-DCs from healthy donors (HD, left), normal pregnant women (NP, middle), or pregnant women with hyperandrogenia (HA, right) are shown.

To analyze DC cytotoxic activity of NP-DCs and HA-DCs, we studied the amount of CD4+ and CD8+ T-cell apoptosis in MLC that was induced by these DCs (Table 3 and Figure 4). NP-DCs and HA-DCs had similar pro-apoptogenic activity against CD3+CD4+ T cells. The number of apoptotic (Annexin V+/PI) CD3+CD4+ T cells in MLC that were induced by DCs from pregnant women in both groups significantly exceeded the number of apoptotic cells in the controls (monocyte-depleted MNC cultures without DCs), but did not differ from each other. However, the percentage of apoptotic (Annexin V+/PI) CD3+CD8+ T cells in MLC that were induced by NP-DCs was significantly higher compared to MLC that were induced by HA-DCs.
Table 3

IFN-α-DC induced apoptosis of CD3 + CD4 + and CD3 + CD8 + Т cells

Annexin V + /PI (%)

Untreated MNCs, n = 8

MNCs + DCs (NP), n = 6

MNCs + DCs (HA), n = 8


0.19 ± 0.05

4.7 ± 1.0*

5.3 ± 1.2*

Т cells





0.17 ± 0.04

15.02 ± 0.3*

11.19 ± 0.9*#

Т cells




Untreated MNCs from healthy donors (control) and MNCs co-cultured with IFNα-DCs from normal pregnant (NP) women or pregnant women with hyperandrogenia (HA) at a MNC-to-DC ratio of 10:1 for 3 days were analyzed for Annexin V/PI double positivity by flow cytometry. Data are presented as mean (± SE) percentages and medians of apoptotic Annexin V+/PI cells within the CD3+CD4+ or CD3+CD8+ (CD4) gates. *, pU <0.05, compared to the control group; #, pU < 0.01, a significant difference between the NP pregnant women and HA pregnant women groups; differences were detected using the Mann–Whitney U test.

Figure 4
Figure 4

T cells undergo enhanced apoptotic cell death when cultured with IFN-α-DCs from pregnant HA + women. IFN-α-DCs were co-cultured with 1 × 105 allogenic MNCs from healthy donors at a 1:10 ratio. After 3 days, apoptosis was evaluated by flow cytometry. Gated CD3+CD4+ T cells were analyzed for Annexin V and PI double positivity. Representative cases of untreated MNCs (left), MNCs co-cultured with IFN-DCs from normal pregnant (NP) women (middle), and MNCs co-cultured with IFN-α-DCs from pregnant women with (HA) hyperandrogenia (right) are shown.


DCs represent unique antigen-presenting cells that are capable of inducing both an immune response and a state of immunological tolerance [10]. The presence of DCs in the decidua, where direct interactions between fetal and maternal cells occurs, makes these cells candidates to be key regulators of immune tolerance in pregnancy [38,39]. Nevertheless, DCs in human pregnancy are not well studied and findings are often contradictory.

In this paper, we demonstrated for the first time that DHEAS, whether elevated during pregnancy in vivo or added in vitro, results in the induction of DC maturation and type 1 T cell stimulatory activity and reduces the apoptosis-inducing activity of monocyte-derived DCs. Monocytes represent a major source of DC precursors and can differentiate into DCs upon exposure to GM-CSF in combination with IL-4 (IL-4-DCs) or IFN-α (IFN-α-DCs) [40,41]. Because DHEAS has been reported to inhibit the secretion of IL-4 [42], we chose a DC generation protocol using GM-CSF and IFN-α. The choice of this protocol was also motivated by the fact that unlike the IL-4-DCs that predominantly activate Th1-responses, IFN-α-DCs can activate both Th1- and Th2-responses [43,44] and possess more pronounced cytotoxic activity [45]. These attributes provide the opportunity to assess the effects of DHEAS on the Th1- and Th2-stimulating activity and cytotoxic effects of DCs.

Our data have shown that in a healthy pregnancy, monocyte-derived IFN-α-DCs possess “tolerogenic” potential, as evidenced by a less mature phenotype and increased priming of type 2 (IL-4) T cell responses compared to DCs from non-pregnant women. Whereas DCs from non-pregnant women induce activated T cell production of IFN-γ, DCs from women with a normal pregnancy predominantly stimulated the production of IL-4. Our data are consistent with the findings of other groups, which demonstrate that the immature phenotype of myeloid DCs, reduced expression of co-stimulatory molecules (CD86 and CD80), and the expression of immunoglobulin-like transcript 3 (ILT-3) were involved in the induction of tolerance and the higher T2-stimulatory activity of decidual DCs in healthy pregnant women [46-48]. Regarding the properties of circulating DCs, Della Bella et al. showed that despite the higher expression of co-stimulatory molecules and the secretion of pro-inflammatory and regulatory cytokines, DCs in a healthy pregnancy were characterized by a low HLA-DR expression, which indicates the “incomplete” activation of these DCs. Moreover, when blood serum from pregnant women was added to control DCs, it induced a DC phenotype associated with low allo-stimulatory activity [49]. For monocyte-derived DCs, Bachy et al. showed that DCs generated by culturing cells from a normal pregnancy in the presence of GM-CSF and IL-4 were phenotypically less mature and characterized by reduced IL-12 and increased IL-10 secretion [50]. However, these authors did not investigate the capacity of these DCs to activate T1 and T2 immune responses.

The second important finding of this study is that DCs from women with elevated levels of DHEAS exhibit no signs of immaturity and, along with a capacity to stimulate the T cell secretion of IL-4, can also activate the production of IFN-γ. Because DHEAS, when added to DCs derived from women with a normal pregnancy, induced T1-stimulatory activity, we suggest that the capacity of HA-DCs to prime type 1 T cell responses in pregnant women with HA could be explained by the elevated levels of this hormone.

Another interesting aspect of this study is our analysis of DC cytotoxic activity. Previously, we showed that IFN-α-DCs from healthy donors can induce the apoptosis of activated NK cells, and the maturation of IFN-α-DCs upon exposure to DHEAS is associated with the down-regulation of cytotoxic activity [51]. Furthermore, we showed that IFN-α-DCs could induce T cell apoptosis, which is largely mediated through the PD-L1 (B7-H1)/PD-1 signaling pathway [47]. As B7-H1 expression on IFN-α-DCs declines along with DC maturation [52], we suggest that DC maturation induced by DHEAS could decrease DC cytotoxic potential against T cells. Indeed, our study showed that in a normal pregnancy DCs were characterized by increased expression of B7-H1 compared to control DCs. Furthermore, in pregnant women with elevated levels of DHEAS, the number of B7-H1+ DCs was significantly lower than in a normal pregnancy. Moreover, the reduced expression of B7-H1 was associated with lower DC cytotoxicity against CD3+CD8+ T cells. Overall, these findings suggest that in pregnant women with elevated levels of DHEAS, the tolerogenic properties of DCs were significantly reduced, which could contribute to impaired “immunosuppressive” re-arrangements of the immune system in HA.

The reduced tolerogenic potential of DCs has been proposed as one of the causative factors of abnormal pregnancy in recurrent pregnancy loss [39] and pre-eclampsia [53]. However, impaired DC functions in pregnant women with increased levels of DHEAS are described herein for the first time. Our findings shed new light on immune–endocrine interactions and their importance in normal and complicated pregnancies.


We report that in healthy pregnancy IFN-α-induced monocyte-derived DCs are characterized by the immature phenotype, the potent ability to stimulate type 2 T cell responses and to induce T cell apoptosis. In contrast, DCs from pregnant women with hyperandrogenia have a mature phenotype, are able to stimulate both type 1 (IFN-γ) and type 2 (IL-4) T cell responses, and differ by lower apoptosis-inducing activity. In addition, DHEAS, when added in vitro to DCs from healthy pregnants, induces the maturation of DCs and increases their ability to activate type 1 T cell responses. This indicates a reduced tolerogenic potential of DCs from pregnant women with HA and reveals a new mechanism involved in the hormonal regulation of DCs mediated by DHEAS.



This study was funded by the Russian Foundation for Basic Research (Number 0904 00525).

Authors’ Affiliations

Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology, 14, Yadrintsevskaya St., 630099 Novosibirsk, Russia
Novosibirsk State University, 2, Pirogova St., 630090 Novosibirsk, Russia


  1. Medawar PB. Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. Symp Soc Exp Biol. 1953;44:320–38.Google Scholar
  2. Taglauer ES, Adams Waldorf KM, Petroff MG. The hidden maternal-fetal interface: events involving the lymphoid organs in maternal-fetal tolerance. Int J Dev Biol. 2010;54(2–3):421–30.View ArticlePubMed CentralPubMedGoogle Scholar
  3. Guleria I, Sayegh MH. Maternal acceptance of the fetus: true human tolerance. J Immunol. 2007;178(6):3345–51.View ArticlePubMedGoogle Scholar
  4. James E, Chai JG, Dewchand H, Macchiarulo E, Dazzi F, Simpson E. Multiparity induces priming tomale-specific minor histocompatibility antigen, HY, in mice and humans. Blood. 2003;102:388–93.View ArticlePubMedGoogle Scholar
  5. Jiang SP, Vacchio MS. Multiple mechanisms of peripheral T cell tolerance to the fetal «allograft». J Immunol. 1998;160:3086–90.PubMedGoogle Scholar
  6. Guerin LR, Prins JR, Robertson SA. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum Reprod. 2009;15(5):517–35.View ArticleGoogle Scholar
  7. Kushwah R, Hu J. Role of dendritic cells in the induction of regulatory T cells. Cell Biosci. 2011;1:1–20.View ArticleGoogle Scholar
  8. Raghupathy R. Pregnancy: success and failure within the Th1/Th2/Th3 paradigm. Semin Immunol. 2001;13:219–27.View ArticlePubMedGoogle Scholar
  9. Sykes L, MacIntyre DA, Yap XJ, Teoh TG, Bennett PR: The Th1:Тh2 dichotomy of pregnancy and preterm labour. Mediators Inflamm 2012, 967629. doi:10.1155/2012/967629Google Scholar
  10. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811.View ArticlePubMedGoogle Scholar
  11. Adams S, O’Neill DW, Bhardwaj N. Recent advances in dendritic cell biology. J Clin Immunol. 2005;25:177–88.PubMedGoogle Scholar
  12. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685–711.View ArticlePubMedGoogle Scholar
  13. Kuwana M, Kaburaki J, Wright TM, Kawakami Y, Ikeda Y. Induction of antigen-specific human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur J Immunol. 2001;31:2547–57.View ArticlePubMedGoogle Scholar
  14. Lutz M: Therapeutic potential of semi-mature dendritic cells for tolerance induction. Front.Immunol. doi: 10.3389/fimmu.2012.00123Google Scholar
  15. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: Cytokine modulation comes of age. Blood. 2006;108:1435–40.View ArticlePubMedGoogle Scholar
  16. Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic responses. Immunol Rev. 2011;241(1):206–27.View ArticlePubMed CentralPubMedGoogle Scholar
  17. Gregori S. Dendritic cells in networks of immunological tolerance. Tissue Antigens. 2010;77:89–99.View ArticleGoogle Scholar
  18. Hu J, Wan Y. Tolerogenic dendritic cells and their potential applications. Immunology. 2011;132(3):307–14.View ArticlePubMed CentralPubMedGoogle Scholar
  19. Tagliani E, Erlebacher A. Dendritic cell function at the maternal–fetal interface. Expert Rev Clin Immunol. 2011;7(5):593–602.View ArticlePubMed CentralPubMedGoogle Scholar
  20. Guo PF, Du MR, Wu HX, Lin Y, Jin LP, Li DJ. Thymic stromal lymphopoietin from trophoblasts induces dendritic cell-mediated regulatory TH2 bias in the decidua during early gestation in humans. Blood. 2010;116:2061–9.View ArticlePubMedGoogle Scholar
  21. Adams KM, Yan Z, Stevens AM, Nelson JL. The changing maternal «self» hypothesis: a mechanism for maternal tolerance of the fetus. Placenta. 2007;28:378–82.View ArticlePubMedGoogle Scholar
  22. Liang J, Sun L, Wang Q. Progesterone regulates mouse dendritic cells differentiation and maturation. Int Immunopharmacol. 2006;6:350–5.View ArticleGoogle Scholar
  23. Segerer SE, Meller N, van den Brandt J, Kapp M, Dietl J. Modulation of maturation and function of dendritic cells by female sex steroid hormones. Amer J Reprod Immunol. 2008;60:86–96.View ArticleGoogle Scholar
  24. Matasiс R, Dietz AB, Vuk-Pavloviс S. Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells. J Leukoc Biol. 1999;66(6):909–14.Google Scholar
  25. Wan H, Versnel MA, Leijten LM, van Helden-Meeuwsen CG, Fekkes D. Modulation of maturation and function of dendritic cells by female sex steroid hormones Chorionic gonadotropin induces dendritic cells to express a tolerogenic phenotype. J Leukoc Biol. 2008;83(4):894–901.View ArticlePubMedGoogle Scholar
  26. Kovats S, Carreras E. Regulation of dendritic cell differentiation and function by estrogen receptor ligands. Cell Immunol. 2008;252:81–90.View ArticlePubMed CentralPubMedGoogle Scholar
  27. Butts CL, Candando KM, Warfel J, Belyavskaya E, D'Agnillo F, Sternberg EM. Progesterone regulation of uterine dendritic cell function in rodents is dependent on the stage of estrous cycle. Mucosal Immunol. 2010;3(5):496–505.View ArticlePubMedGoogle Scholar
  28. Blois SM, Kammerer U, Alba Soto C, Tometten MC, Shaikly V, Barrientos G, et al. Dendritic cells: key to fetal tolerance? Biol Reprod. 2007;77:590–8.View ArticlePubMedGoogle Scholar
  29. Seledtsova NV, Khonina NA, Dudareva AV, Tihonova MA, Ostanin AA, Pasman NM, et al. Characteristic of natural cytotoxic cells and regulatory T-lymphocytes in pregnant women with hyperandrogenia. Immunology. 2007;3:151–5 (in Russian).Google Scholar
  30. Winger EE, Reed JL. Low circulating CD4+CD25+Foxp3+ T regulatory cell levels predict miscarriage risk in newly pregnant women with a history of failure. Am J Reprod Immunol. 2011;66:320–8.View ArticlePubMedGoogle Scholar
  31. Shakhar K, Rosenne E, Loewenthal R, Shakhar G, Carp H, Ben-Eliyahu S. High NK cell activity in recurrent miscarriage: what are we really measuring? Hum Reprod. 2006;21(9):2421–5.View ArticlePubMedGoogle Scholar
  32. Moran C, Azziz R, Weintrob N, Witchel SF, Rohmer V, Dewailly D, et al. Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. J Clin Endocrinol Metabolism. 2006;91(9):3451–6.View ArticleGoogle Scholar
  33. Gurbuz B, Yalti S, Fiçicioglu C, Ozden S, Yildirim G, Sayar C. Basal hormone levels in women with recurrent pregnancy loss. Gynecol Endocrinol. 2003;17(4):317–21.View ArticlePubMedGoogle Scholar
  34. Powell JM, Sonnenfeld G. The effects of Dehydroepiandrosterone (DHEA) on in vitro spleen cell proliferation and cytokine production. J Interferon Cytokine Res. 2006;26(1):34–9.View ArticlePubMedGoogle Scholar
  35. Seledtsova NV, Khonina NA, Tikhonova MA, Ostanin AA, Pasman NМ, Chernykh ER. Effect of dehydroepiandrosterone sulfate on the phenotype and functions of dendritic cells in vitro. Med Immunol. 2007;9(6):589–96 (in Russian).Google Scholar
  36. Tyrinova TV, Leplina OY, Tikhonova MA, Sakhno LV, Ostanin AA, Chernykh ER. Characteristics of signaling pathways mediating a cytotoxic activity of dendritic cells upon activated T lymphocytes and NK cells. Med Immunol. 2012;14(1–2):43–50 (in Russian).Google Scholar
  37. Sakhno LV, Tikhonova MA, Tyrinova TV, Leplina OY, Shevela EY at al: Cytotoxic Activity of Dendritic Cells as a Possible Mechanism of Negative Regulation of T Lymphocytes in Pulmonary Tuberculosis. Clinical and Developmental Immunology 2012, Article ID 628635, 9. doi:10.1155/2012/628635Google Scholar
  38. Kammerer U, Kruse A, Barrientos G, Arck PC, Blois SM. Role of dendritic cells in the regulation of maternal immune responses to the fetus during mammalian gestation. Immunol Invest. 2008;37(5):499–533.View ArticlePubMedGoogle Scholar
  39. Askelund K, Liddell HS, Zanderigo AM, Fernando NS, Khong TY, Stone PR, et al. CD83(+) dendritic cells in the decidua of women with recurrent miscarriage and normal pregnancy. Placenta. 2004;25:140–5.View ArticlePubMedGoogle Scholar
  40. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical applications. J Immunol Meth. 1999;223:1–15.View ArticleGoogle Scholar
  41. Santini S, Pucchini T, Lapenta C, Parlato S, Logozzi M, Belardelli F, et al. A new type 1 IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells. Stem Cells. 2003;21:357–62.View ArticlePubMedGoogle Scholar
  42. Tabata N, Tagami H, Terui T. Dehydroepiandrosterone may be one of the regulators of cytokine production in atopic dermatitis. Arch Dermatol Res. 1997;289(7):410–4.View ArticlePubMedGoogle Scholar
  43. Santini S, Lapenta C, Logozzi M, Parlato S, Spada M, Pucchio T, et al. Type I Interferon as a powerful adjuvant for monocyte-derived dendritic cells development and activity in vitro and in HU-PBL-SCID mice. J Exp Med. 2000;191:1777–88.View ArticlePubMed CentralPubMedGoogle Scholar
  44. Della Bella S, Nicola S, Riva A, Biasin M, Clerici M, Villa ML. Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon–α. J Leukocyte Biol. 2004;75:106–16.View ArticlePubMedGoogle Scholar
  45. Papewalis C, Jacobs B, Wuttke M, Ullrich E, Baehring T, Fenk R, et al. IFN-a skews monocytes into CD56 + -expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol. 2008;80(3):1462–70.View ArticleGoogle Scholar
  46. Gardner L, Moffett A. Dendritic cells in the human decidua. Biol Reprod. 2003;69:1438–46.View ArticlePubMedGoogle Scholar
  47. Ban YL, Kong BH, Qu X, Yang QF, Ma YY. BDCA-1+, BDCA-2+ and BDCA-3+ dendritic cells in early human pregnancy deciduas. Clin Exp Immunol. 2008;151:399–406.View ArticlePubMed CentralPubMedGoogle Scholar
  48. Miyazaki S, Tsuda H, Sakai M, Hori S, Sasaki Y, Futatani T, et al. Predominance of Th2-promoting dendritic cells in early human pregnancy decidua. J Leukoc Biol. 2003;74:514–22.View ArticlePubMedGoogle Scholar
  49. Della Bella S, Giannelli S, Cozzi V, Signorelli V, Cappelletti M, et al. Incomplete activation of peripheral blood dendritic cells during healthy human pregnancy. Clin Exp Immunol. 2011;164(2):180–92.View ArticlePubMed CentralPubMedGoogle Scholar
  50. Bachy V, Williams DJ, Ibrahim MA. Altered dendritic cell function in normal pregnancy. J Reprod Immunol. 2008;78(1):11–21.View ArticlePubMedGoogle Scholar
  51. Leplina O, Yu Tikhonova MA, Tyrinova TV, Alyamkina EA, Dolgova EV, Bogachev SS, et al. Comparative characteristic of phenotype and cytokine-secretory activity of human dendritic cells generated in vitro with IFN-alpha and IL-4. Immunology. 2012;33(2):60–5. in Russian).Google Scholar
  52. Seledtsova NV, Khonina NA, Tihonova MA, Pasman NM, Ostanin AA, Chernykh RR, et al. The interaction of NK-cells with dendritic cells modified by dehydroepiandrosterone sulfate. Immunology. 2008;2:80–4 (in Russian).Google Scholar
  53. Huang SJ, Chen CP, Schatz F, Rahman M, Abrahams VM, Lockwood CJ. Pre-eclampsia is associated with dendritic cell recruitmnt into the uterine decidua. J Pathol. 2008;214:328–36.View ArticlePubMedGoogle Scholar


© Chernykh et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.